8-K - Femasys Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Femasys Inc. announced financial results for the year ended December 31, 2025, reporting sales of $2.3 million, up 40.8% from 2024, and a net loss of $18.6 million with cash runway into Q3 2026.

Key Takeaways

1Sales rose 40.8% to $2,293,313 in 2025 from $1,629,108 in 2024, driven by FemBloc.

2Net loss improved to $18.6 million or ($0.47) per share in 2025 from $18.8 million or ($0.85) per share in 2024.

3Cash and equivalents stood at $9.3 million as of December 31, 2025, sufficient into Q3 2026.

4Initiated FINALE pivotal trial enrollment for FemBloc toward U.S. FDA approval.

5Completed $12 million financing to support clinical and commercial efforts.

6R&D expenses decreased 7.8% to $7.6 million in 2025 due to product commercialization.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

| Results of Operations and Financial Condition. | |---|---| On March 31, 2026 Femasys Inc. (the “Company”) announced its financial results for the year ended D

Financial Results

9.01

| Financial Statements and Exhibits. | |---|---| (d) Exhibits. | Exhibit No. | Description | |---|---| | | | | 99.1 | Press Release of Femasys Inc. dated March

Exhibits Only

Source Document

Results of Operations

Year Ended December 31, 2025

Metric	Value	Prior Period
Sales	$2.3M	$1.6M
Net loss	$-18.6M	$-18.8M
Net loss per share attributable to common stockholders, basic and diluted	$-0.47	$-0.85

Exhibits (2)

8-K

99.1

EXHIBIT 99.1